Recombinant RelB Monoclonal Antibody

SKU: AN300687L

Size::50μL

Storage:Store at -20℃ Valid for 12 months. Avoid freeze / thaw cycles.

Shipping:Ice bag

Exp date:12 months

Category ID_II:Primary Antibodies

Category ID_III:Recombinant Antibodies;Monoclonal Antibodies

Abbreviation:RelB

Target Synonym:RELB;I-REL;IREL;REL-B;I REL;Nuclear factor of kappa light polypeptide gene enhancer in B cells 3;Reticuloendotheliosis viral oncogene homolog B;Transcription factor Rel B;Transcription factor RelB;v rel avian reticuloendotheliosis viral oncogene homolog B;v rel reticuloendotheliosis viral oncogene homolog B

Research Areas:Cell Biology;Signal Transduction;Epigenetics and Nuclear Signaling;Cancer

Conjugation:Unconjugated

Host:Rabbit

Species reactivity:Human;Mouse;Rat

Application:WB

Isotype:IgG,κ

Clonality:Monoclonal;Recombinant

Clone NO.:6A8

UNIProt ID:Q01201

Accession:

Background:Was originally (PubMed:1577270) thought to inhibit the transcriptional activity of nuclear factor NF-kappa-B.,domain:Both N- and C-terminal domains are required for transcriptional activation.,NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA/p65 or REL. Stimulates promoter activity in the presence of NFKB2/p49.,induction:By mitogens.,PTM:Phosphorylation at 'Thr-103' and 'Ser-573' is followed by proteasomal degradation.,similarity:Contains 1 RHD (Rel-like) domain.,subunit:Component of the NF-kappa-B RelB-p50 complex. Component of the NF-kappa-B RelB-p52 complex. Self-associates; the interaction seems to be transient and may prevent degradation allowing for heterodimer formation with p50 or p52. Interacts with NFKB1/p50, NFKB2/p52 and NFKB2/p100. Interacts with NFKBID.

Concentration:0.2 mg/mL

Immunogen:Recombinant Human RelB protein

Buffer:PBS, 50% glycerol, 0.05% Proclin 300, 0.05% protein protectant.

Purification method:Protein A

Dilution:WB 1:2000-1:10000

Calculated MW:62 kDa

ObservedMW:62 kDa